Zingmet-TG Tablet SR is a combination oral antidiabetic medication containing Metformin 500 mg and Teneligliptin 20 mg, formulated to improve glycemic control in patients with type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, enhancing peripheral glucose uptake, and improving insulin sensitivity, thereby reducing fasting and postprandial blood glucose levels. Teneligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, prolongs the action of incretin hormones, which increases insulin secretion and decreases glucagon release in a glucose-dependent manner, contributing to improved postprandial glycemic control. The sustained-release formulation of Zingmet-TG ensures a gradual release of active ingredients, promoting better patient compliance and stable plasma drug concentrations. This combination is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when monotherapy with either agent is inadequate. It is essential to monitor renal function periodically during therapy, as Metformin is contraindicated in patients with significant renal impairment. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, while Teneligliptin is generally well tolerated. Zingmet-TG should be prescribed under medical supervision with appropriate lifestyle modifications for optimal therapeutic outcomes.